First Turn Management, Llc

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$895.1M
Q ending 2026-03-31
Prior quarter
$875.2M
Q ending 2025-12-31
Change
+2.3% QoQ · +80.4% YoY
Positions
33
reported holdings

Largest positions

All 33 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
United Therapeutics Corp DelUTHRShares$62.1M105K
Abivax SaABVXShares$51.9M466K
Bridgebio Pharma IncBBIOShares$51.7M696K
Xenon Pharmaceuticals IncXENEShares$45.8M787K
Revolution Medicines IncRVMDShares$45.5M468K
Apogee Therapeutics IncAPGEShares$43.2M514K
Insmed IncINSMShares$40.6M248K
Nuvalent Inc5AXShares$37.9M370K
Mirum Pharmaceuticals IncMIRMShares$37.0M400K
Cogent Biosciences IncCOGTShares$36.5M947K
Roivant Sciences LtdShares$33.0M1.2M
Axsome Therapeutics Inc.AXSMShares$31.9M189K
Ideaya Biosciences IncIDYAShares$29.1M874K
Oric Pharmaceuticals IncORICShares$25.6M2.0M
Enliven Therapeutics IncELVNShares$24.5M624K
Celcuity IncCELCShares$24.0M211K
Scholar Rock Hldg CorpSRRKShares$21.9M446K
Kymera Therapeutics IncKYMRShares$21.2M255K
Cytokinetics IncCYTKShares$18.7M284K
Dianthus Therapeutics IncDNTHShares$18.5M221K
Palvella Therapeutics Inc NePVLAShares$18.5M148K
Newamsterdam Pharma CompanyShares$17.9M558K
Viridian Therapeutics IncVRDNShares$17.8M911K
Ascendis Pharma A/SShares$17.5M76K
Fulcrum Therapeutics IncFULCShares$17.3M2.3M
Terns Pharmaceuticals Inc430Shares$17.2M327K
Vera Therapeutics IncVERAShares$17.0M422K
Natera IncNTRAShares$16.2M81K
Erasca IncERASShares$14.0M868K
Praxis Precision Medicines IPRAXShares$13.7M42K
Olema Pharmaceuticals IncOLMAShares$11.5M769K
Uniqure NvShares$10.1M615K
Moonlake ImmunotherapeuticsMLTXShares$5.9M316K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.